ABSTRACT
We have used confocal microscopy to elucidate the effects of antiandrogens on nuclear localization of the androgen receptor (AR) with its transcriptional coactivator GRIP1. We show that the agonist-activated AR recruits GRIP1 to colocalize with the receptor in the nucleoplasm. By contrast, AR complexed to the antiandrogens hydroxyflutamide and bicalutamide fails to influence nuclear distribution of GRIP1. Likewise, the non-steroidal antiandrogens prevent the agonist-induced AR-GRIP1 colocalization from occurring. Androgen antagonists affect nuclear redistribution of AR-GRIP1 in a fashion that parallels their effects on the transcriptional activity of AR, in that the pure antagonists block GRIP1-dependent activation of AR function, whereas the mixed antagonist/agonist cyproterone acetate promotes both AR-driven redistribution of GRIP1 and activation of AR by GRIP1.
Subject(s)
Androgen Antagonists/pharmacology , Cell Nucleus/drug effects , Flutamide/analogs & derivatives , Receptors, Androgen/metabolism , Transcription Factors/metabolism , Active Transport, Cell Nucleus/drug effects , Active Transport, Cell Nucleus/physiology , Androgens/metabolism , Anilides/pharmacology , Animals , COS Cells/metabolism , Cell Nucleus/metabolism , Chlorocebus aethiops , Cyproterone Acetate/pharmacology , Flutamide/pharmacology , Nitriles , Nuclear Receptor Coactivator 2 , Subcellular Fractions/metabolism , Tosyl Compounds , Transcription Factors/physiology , Transcriptional Activation/drug effects , Transcriptional Activation/physiologyABSTRACT
The small nuclear C(3)HC(4) finger protein (SNURF), RNF4, acts as transcriptional coactivator for both steroid-dependent and -independent promoters such as those driven by androgen response elements and GC boxes, respectively. However, SNURF does not possess intrinsic transcription activation function, and the precise molecular mechanism of its action is unknown. We have studied herein the interaction of SNURF with DNA in vitro. SNURF binds to linear double-stranded DNA with no apparent sequence specificity in a cooperative fashion that is highly dependent on the length of the DNA fragment used. SNURF interacts efficiently with both supercoiled circular and four-way junction DNA, and importantly, it also recognizes nucleosomes. An intact RING structure of SNURF is not mandatory for DNA binding, whereas mutations of specific positively charged residues in the N terminus (amino acids 8-11) abolish DNA binding. Interestingly, the ability of SNURF to interact with DNA is associated with its capability to enhance transcription from promoters containing GC box elements. Because SNURF can interact with both DNA and protein (transcription) factors, it may promote assembly of nucleoprotein structures.
Subject(s)
Nuclear Proteins/metabolism , Nuclear Proteins/physiology , Transcription Factors/metabolism , Transcription Factors/physiology , Amino Acid Sequence , Animals , COS Cells , DNA/metabolism , DNA, Superhelical/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , DNA-Binding Proteins/physiology , Molecular Sequence Data , Mutation , Nuclear Proteins/genetics , Nucleosomes/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Transcription Factors/genetics , Transcriptional Activation , TransfectionABSTRACT
Modification by SUMO-1 is proposed to play a role in protein targeting and/or stability. The SUMO-1-conjugating enzyme Ubc9 interacts with androgen receptor (AR), a ligand-activated transcription factor belonging to the steroid receptor superfamily. We show here that AR is covalently modified by SUMO-1 (sumoylated) in an androgen-enhanced fashion and identify the principal acceptor site in the N-terminal domain of AR. Substitutions of sumoylated Lys residues enhanced transcriptional activity of AR without influencing its transrepressing activity. Interestingly, the same Lys residues form the cores of the recently described transcriptional synergy control motifs in AR [Iñiguez-Lluhi, J. A. & Pearce, D. (2000) Mol. Cell. Biol. 20, 6040-6050]. These motifs, which match perfectly with the sumoylation consensus sequence, are also present in the N-terminal domains of glucocorticoid, mineralocorticoid, and progesterone receptor. Taken together, our data suggest that reversible sumoylation is a mechanism for regulation of steroid receptor function.
Subject(s)
Receptors, Androgen/metabolism , Ubiquitin-Conjugating Enzymes , Ubiquitins/metabolism , Animals , Binding Sites , COS Cells , Catalysis , Chlorocebus aethiops , HeLa Cells , Humans , Ligases/metabolism , Receptors, Androgen/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , SUMO-1 Protein , Transcription, Genetic , Ubiquitins/geneticsABSTRACT
Androgen receptor (AR) belongs to the superfamily of nuclear hormone receptors that employ complex molecular mechanisms to guide the development and physiological functions of their target tissues. Our recent work has led to the identification of four novel proteins that recognize AR zinc-finger region (ZFR) both in vivo and in vitro. One is a small nuclear RING-finger protein that possesses separate interaction interfaces for AR and for other transcription activators such as Sp1. The second is a nuclear serine/threonine protein kinase (androgen-receptor-interacting nuclear protein kinase; ANPK); however, the receptor itself does not seem to be a substrate for this kinase. The third one is dubbed androgen-receptor-interacting protein 3 (ARIP3) and is a novel member of the PIAS (protein inhibitor of activated STAT) protein family. The fourth protein, termed ARIP4, is a nuclear ATPase that belongs to the SNF2-like family of chromatin remodelling proteins. All four proteins exhibit a punctate nuclear pattern when expressed in cultured cells. Each protein modulates AR-dependent transactivation in co-transfection experiments; their activating functions are not restricted to AR. Current work is aimed at elucidating the biochemical and functional properties of these AR-interacting proteins and at finding the partner proteins that form complexes with them in vivo.
Subject(s)
Cell Nucleus/metabolism , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Adenosine Triphosphatases/metabolism , Animals , Carrier Proteins/metabolism , Chromatin/metabolism , DNA Helicases , DNA-Binding Proteins/metabolism , Down-Regulation , Gene Expression Regulation , Humans , Male , Nuclear Proteins/metabolism , Prostatic Neoplasms/metabolism , Protein Inhibitors of Activated STAT , Protein Serine-Threonine Kinases/metabolism , Proteins/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Transfection , Ubiquitin-Protein Ligases , X Chromosome , Zinc FingersABSTRACT
The androgen receptor (AR) is a transcription factor that mediates androgen action. We have used the green fluorescent protein (GFP) technique to investigate dynamics of nuclear trafficking of human AR in living cells. In the absence of ligand, the GFP-AR fusion protein is distributed between cytoplasm and nuclei. Androgen exposure leads to a rapid and complete import of GFP-AR to nuclei of CV-1 cells (>=90% nuclear in 30 minutes), whereas a pure antiandrogen, Casodex, elicits a slower (<40% nuclear in 30 minutes) and incomplete transfer. Unliganded ARs with mutations in the basic amino acids of the bipartite nuclear localization signal (NLS) within the second zinc finger and the hinge region are predominantly cytoplasmic and their androgen-dependent nuclear import is severely compromised ((3/4)20% nuclear in 30 minutes). Interestingly, substitutions of the Leu residues flanking the bipartite NLS lead to inefficient nuclear transfer in response to androgen ((3/4)20% nuclear in 30 minutes). The ligand-binding domain of AR, which represses bipartite NLS activity, contains an agonist-specific NLS. The small nuclear RING finger protein SNURF, which interacts with AR through a region overlapping with the bipartite NLS, facilitates AR import to nuclei and retards its export on hormone withdrawal. More AR is associated with the nuclear matrix in the presence than absence of coexpressed SNURF. We suggest that the SNURF-mediated tethering of AR in nuclei represents a novel mechanism for activating steroid receptor functions.
Subject(s)
Cell Nucleus/metabolism , Nuclear Proteins/physiology , Receptors, Androgen/metabolism , Transcription Factors/physiology , Amino Acid Sequence , Androgen Receptor Antagonists , Androgens/metabolism , Animals , Biological Transport , COS Cells , Cell Line , Green Fluorescent Proteins , Humans , Indicators and Reagents/pharmacology , Leucine/genetics , Luminescent Proteins/genetics , Luminescent Proteins/pharmacology , Molecular Sequence Data , Nuclear Localization Signals/genetics , Nuclear Matrix/metabolism , Nuclear Proteins/genetics , Point Mutation , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Recombinant Fusion Proteins/metabolism , Sequence Deletion , Transcription Factors/genetics , Transcription, Genetic , Transfection , Zinc Fingers/geneticsABSTRACT
Ubc9, a homologue of the class E2 ubiquitin-conjugating enzymes, has recently been shown to catalyze conjugation of a small ubiquitin-like molecule-1 (SUMO-1) to a variety of target proteins. SUMO-1 modifications have been implicated in the targeting of proteins to the nuclear envelope and certain intranuclear structures and in converting proteins resistant to ubiquitin-mediated degradation. In the present work, we find that Ubc9 interacts with the androgen receptor (AR), a member of the steroid receptor family of ligand-activated transcription factors. In transiently transfected COS-1 cells, AR-dependent but not basal transcription is enhanced by the coexpression of Ubc9. The N-terminal half of the AR hinge region containing the C-terminal part of the bipartite nuclear localization signal is essential for the interaction with Ubc9. Deletion of this part of the nuclear localization signal, which does not completely prevent the transfer of AR to the nucleus, abolishes the AR-Ubc9 interaction and attenuates the transcriptional response to cotransfected Ubc9. The C93S substitution of Ubc9, which prevents SUMO-1 conjugation by abrogating the formation of a thiolester bond between SUMO-1 and Ubc9, does not influence the capability of Ubc9 to stimulate AR-dependent transactivation, implying that Ubc9 is able to act as an AR coregulator in a fashion independent of its ability to catalyze SUMO-1 conjugation.
Subject(s)
Ligases/metabolism , Receptors, Androgen/metabolism , Transcription, Genetic , Ubiquitin-Conjugating Enzymes , Amino Acid Sequence , Animals , Binding Sites , COS Cells , DNA/metabolism , Molecular Sequence Data , Mutagenesis, Site-Directed , Protein Binding , Receptors, Androgen/genetics , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , SUMO-1 Protein , Ubiquitins/metabolism , YeastsABSTRACT
We have characterized a novel partner for androgen receptor (AR), termed ARIP3, that interacts with the DNA-binding domain/zinc finger region of AR and is predominantly expressed in the testis. Rat ARIP3 is a nuclear protein comprising 572 amino acids. It modulates AR-dependent but not basal transcription, suggesting that ARIP3 acts as an AR transcriptional coregulator. Except for the C-terminal AR-interacting domain, ARIP3 contains distinct regions that are also present in two recently described proteins, a protein inhibitor of activated Stat3 and an RNA helicase II-interacting protein (Gu/RH-II binding protein). Conserved structural features of these proteins indicate the existence of a gene family involved in the regulation of various transcription factors. Collectively, ARIP3 belongs to a novel nuclear protein family and is perhaps the first tissue-specific coregulator of androgen receptor.
Subject(s)
Nuclear Proteins/metabolism , Receptors, Androgen/physiology , Testis/metabolism , Amino Acid Sequence , Animals , COS Cells , DNA-Binding Proteins , Male , Molecular Sequence Data , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Protein Binding , Protein Inhibitors of Activated STAT , Rats , Receptors, Androgen/metabolism , Sequence Homology, Amino Acid , Subcellular Fractions/metabolism , Transcription, Genetic/physiology , Transfection , Ubiquitin-Protein Ligases , Zinc FingersABSTRACT
Androgen receptor (AR) belongs to the nuclear receptor superfamily and mediates the biological actions of male sex steroids. In this work, we have characterized a novel 130-kDa Ser/Thr protein kinase ANPK that interacts with the zinc finger region of AR in vivo and in vitro. The catalytic kinase domain of ANPK shares considerable sequence similarity with the minibrain gene product, a protein kinase suggested to contribute to learning defects associated with Down syndrome. However, the rest of ANPK sequence, including the AR-interacting interface, exhibits no apparent homology with other proteins. ANPK is a nuclear protein that is widely expressed in mammalian tissues. Its overexpression enhances AR-dependent transcription in various cell lines. In addition to the zinc finger region, ligand-binding domain and activation function AF1 of AR are needed, as the activity of AR mutants devoid of these domains was not influenced by ANPK. The receptor protein does not appear to be a substrate for ANPK in vitro, and overexpression of ANPK does not increase the extent of AR phosphorylation in vivo. In view of this, it is likely that ANPK-mediated activation of AR function is exerted through modification of AR-associated proteins, such as coregulatory factors, and/or through stabilization of the receptor protein against degradation.
Subject(s)
Nuclear Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Receptors, Androgen/metabolism , Amino Acid Sequence , Animals , Base Sequence , Binding Sites , CHO Cells , COS Cells , Cell Line , Cell Nucleus/enzymology , Cricetinae , DNA, Complementary , Gene Expression , Humans , Male , Molecular Sequence Data , Nuclear Proteins/genetics , PC12 Cells , Protein Serine-Threonine Kinases/genetics , Rats , Saccharomyces cerevisiae , Sequence Homology, Amino Acid , Transcriptional ActivationABSTRACT
Using the DNA-binding domain of androgen receptor (AR) as a bait in a yeast two-hybrid screening, we have identified a small nuclear RING finger protein, termed SNURF, that interacts with AR in a hormone-dependent fashion in both yeast and mammalian cells. Physical interaction between AR and SNURF was demonstrated by coimmunoprecipitation from cell extracts and by protein-protein affinity chromatography. Rat SNURF is a highly hydrophilic protein consisting of 194 amino acid residues and comprising a consensus C3HC4 zinc finger (RING) structure in the C-terminal region and a bipartite nuclear localization signal near the N terminus. Immunohistochemical experiments indicated that SNURF is a nuclear protein. SNURF mRNA is expressed in a variety of human and rat tissues. Overexpression of SNURF in cultured mammalian cells enhanced not only androgen, glucocorticoid, and progesterone receptor-dependent transactivation but also basal transcription from steroid-regulated promoters. Mutation of two of the potential Zn2+ coordinating cysteines to serines in the RING finger completely abolished the ability of SNURF to enhance basal transcription, whereas its ability to activate steroid receptor-dependent transcription was maintained, suggesting that there are separate domains in SNURF that mediate interactions with different regulatory factors. SNURF is capable of interacting in vitro with the TATA-binding protein, and the RING finger domain is needed for this interaction. Collectively, we have identified and characterized a ubiquitously expressed RING finger protein, SNURF, that may function as a bridging factor and regulate steroid receptor-dependent transcription by a mechanism different from those of previously identified coactivator or integrator proteins.
Subject(s)
Gene Expression Regulation , Nuclear Proteins/metabolism , Receptors, Androgen/metabolism , Transcription Factors/metabolism , Transcription, Genetic , Zinc Fingers , Amino Acid Sequence , Animals , CHO Cells , COS Cells , Cell Line , Cloning, Molecular , Cricetinae , Gene Library , HeLa Cells , Humans , Male , Mice , Molecular Sequence Data , Nuclear Proteins/biosynthesis , Nuclear Proteins/chemistry , Rats , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/metabolism , TATA Box , Testis/metabolism , Transcription Factors/biosynthesis , Transcription Factors/chemistry , Transcriptional Activation , Transfection , Ubiquitin-Protein LigasesABSTRACT
Promoter interference assay was employed to examine in intact cells the roles of the functional domains of androgen receptor (AR) and the ligand for specific DNA interactions using a cytomegalovirus-(androgen response element)-chloramphenicol acetyltransferase reporter (pCMV-ARE2-CAT). Native rat and human ARs interfered with pCMV-ARE2-CAT expression in a hormone-dependent fashion. Low steroid-independent interference seemed to occur because of the ligand binding domain (LBD), which was transcriptionally inhibitory also in a heterologous context. AR devoid of LBD (rARDelta641-902) decreased pCMV-ARE2-CAT activity by 50%. The rARDelta46-408 mutant devoid of the NH2-terminal transcription activation region exhibited ligand-dependent promoter interference of a similar magnitude. Ligand and DNA binding-deficient mutants (hARM807R and rARC562G, respectively) did not influence pCMV-ARE2-CAT expression, although hARM807R binds to ARE in vitro. Non-steroidal anti-androgens casodex and hydroxyflutamide antagonized agonist-dependent promoter interference, whereas cyproterone acetate, RU 56187, RU 57073, and RU 59063 were partial agonists/antagonists. Collectively, interaction of ARs with ARE in intact cells does not require the presence of the COOH-terminal or NH2-terminal domain and/or their interaction. In the context of native AR, however, the androgen-induced conformational change in LBD is mandatory for generation of a transcriptionally competent receptor that binds to DNA in intact cells.
Subject(s)
Androgens/genetics , Receptors, Androgen/metabolism , Androgen Antagonists/metabolism , Androgens/chemistry , Androgens/metabolism , Animals , Binding Sites , Cells, Cultured , DNA/metabolism , Genes, Reporter , Humans , Ligands , Promoter Regions, Genetic , Rats , Receptors, Androgen/chemistry , Transcription, Genetic , TransfectionABSTRACT
To study the effects of nandrolone laureate (19-nortestosterone) on muscle hypertrophy and concentration of androgen receptors (AR), biopsy specimens were taken from the middle gluteal muscle of 6 Finnhorse trotters (geldings and mares) undergoing training before, immediately after, and 13 weeks after a 14-week treatment with nandrolone. Another 6 similarly trained horses served as controls. An additional 10 mares and 10 geldings were used to study annual variation in muscle concentration of AR. AR was immunohistochemically localized in the nuclei. AR concentration remained constant during the first 14 weeks of the study, but increased significantly during the 13-week follow-up period in both groups. This finding can be explained by the annual variation in AR. In the anabolic steroid (AS)-treated horses, but not in the controls (C), the cross-sectional area of the type I fibres increased significantly during the treatment period, and the percentage of type IIA fibres correlated positively with AR concentration at the end of nandrolone treatment. In the AS group, the concentration of DNA decreased during the 13-week follow-up period, and the percentage of H-chains in the isoenzymes of LDH increased. Protein concentration increased in both groups during the follow-up period. Glycogen content and the activity of citrate synthase in muscle during the study remained unchanged. It can thus be concluded that AS produce differing effects on type I and type II fibres, and the AR concentration in equine muscle may contribute to the change observed in the middle gluteal muscle.
Subject(s)
Anabolic Agents/pharmacology , Body Composition/drug effects , Horses/metabolism , Muscle, Skeletal/chemistry , Nandrolone/pharmacology , Receptors, Androgen/analysis , Anabolic Agents/administration & dosage , Anabolic Agents/blood , Animals , Body Composition/physiology , Dose-Response Relationship, Drug , Female , Horses/blood , Horses/physiology , Male , Muscle, Skeletal/drug effects , Muscle, Skeletal/physiology , Nandrolone/administration & dosage , Nandrolone/blood , Receptors, Androgen/drug effects , Receptors, Androgen/metabolismABSTRACT
Glycodelin is a glycoprotein with potent immunosuppressive and contraceptive activities. It reacts with antibodies against placental protein 14, or progesterone-associated endometrial protein, and has a unique carbohydrate structure. Previous nomenclature is misleading, because glycodelin is neither synthesized in the placenta nor is it endometrium specific. No ovarian synthesis of glycodelin has been demonstrated. We present evidence for glycodelin synthesis in the human ovary and ovarian tumors. In follicular phase, immunoperoxidase staining of microwave-treated tissue sections employing affinity-purified polyclonal antibodies localized glycodelin to areas of stromal cell condensation in ovarian cortex, theca interna, and the granulosa. In luteal phase, cortical stroma was negative or only weakly positive, whereas glycodelin was present in theca interna of the corpus luteum and luteinized granulosa cells and also in corpus albicans and Leydig cells of the ovarian hilus. In situ hybridization gave negative results for glycodelin mRNA in normal ovary, whereas in ovarian tumors strong expression of both the glycodelin mRNA and the protein were found in benign and malignant serous cystadenomas, mucinous ovarian tumors being negative. We conclude that glycodelin is synthesized in human ovarian tumors, and its occurrence in normal human ovary may represent either synthesis or a site of glycodelin action.
Subject(s)
Contraceptive Agents, Female/pharmacology , Glycoproteins/analysis , Glycoproteins/physiology , Immunosuppressive Agents/pharmacology , Ovarian Neoplasms/chemistry , Ovary/chemistry , Pregnancy Proteins/analysis , Pregnancy Proteins/physiology , Adult , Aged , Aged, 80 and over , Blotting, Northern , Corpus Luteum/chemistry , Female , Glycodelin , Glycoproteins/genetics , Humans , Immunohistochemistry , In Situ Hybridization , Middle Aged , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Ovary/cytology , Ovary/metabolism , Pregnancy Proteins/genetics , RNA, Messenger/analysis , RNA, Messenger/metabolismABSTRACT
In situ hybridization was used to localize xanthine dehydrogenase (XDH) mRNA in horse skeletal muscle. Capillary endothelial cells were found to express XDH, but muscle cells did not give any signal. The digoxigenin-labelled probe was produced by PCR with primers based on the cDNA sequence of mouse XDH and horse lung cDNAs. A 4.3 kb mRNA was detected in a Northern blot.